85
Views
7
CrossRef citations to date
0
Altmetric
Drug Profile

Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

, &
Pages 1383-1390 | Published online: 10 Jan 2014
 

Abstract

On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.

Financial & competing interests disclosure

Stephen J Nicholls has received research support from AstraZeneca, Novartis, Eli Lilly, Resverlogix, Anthera, Roche, LipoScience and Karo Bio, and consulting fees/honoraria from AstraZeneca, Merck, Takeda, Roche, Omthera, sanofi-aventis, CSL Behring and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.